Ultragenyx Pharmaceutical Inc.
RAREUltragenyx Pharmaceutical Inc. (RARE) is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. Established to address the unmet medical needs of patients with serious, life-threatening conditions, the company specializes in innovative treatments targeting underlying genetic causes.
Company News
Ultragenyx Pharmaceutical Inc. granted 44,409 restricted stock units to 15 newly hired non-executive officers on June 16, 2026, as an inducement for employment. The awards were approved by the compensation committee under the Ultragenyx Employment Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over...
A class action lawsuit has been filed against Ultragenyx Pharmaceutical for allegedly providing misleading statements about setrusumab's efficacy in treating Osteogenesis Imperfecta. The company claimed the drug would reduce fracture rates, but Phase III Orbit and Cosmic studies failed to achieve statistical significance on primary endpoints. Ult...
Rosen Law Firm is notifying investors in BlackRock TCP Capital Corp. (TCPC) and other companies about ongoing securities class action lawsuits. The firm is seeking a lead plaintiff by the April 6, 2026 deadline. According to the lawsuit, BlackRock TCP made materially false statements regarding investment valuations, portfolio quality, and net ass...
Rosen Law Firm has filed securities class action lawsuits against Ultragenyx Pharmaceutical, Kyndryl Holdings, and Vital Farms, urging investors with significant losses to secure legal counsel before upcoming deadlines. The Ultragenyx case alleges the company made misleading statements about setrusumab's effectiveness in treating Osteogenesis Imp...
A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. alleging that the company made false and misleading statements regarding its Phase III Orbit study for setrusumab treatment of Osteogenesis Imperfecta. The complaint claims Ultragenyx failed to disclose risks associated with basing optimistic interim analysis benchmarks ...
